Your provider will review your health history and medications to ensure treatment is appropriate and safe for you
Please note that the next dose might be lower or higher depending on a patients signs and symptoms (for instance, a higher dose might be required if a patient needs to receive increased glycemic control)
So far, no significant hypoglycaemia signal has been seen, likely because GLP-1 and GIP agonism counterbalance glucagons glucose-raising effect, but this remains an area of ongoing surveillance
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study
Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial